-
May 07, 2026
Gilead Sciences Announces First Quarter 2026 Financial Results
-
February 11, 2026
Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results
-
December 23, 2025
Seladelpar Granted Approval for Primary Biliary Cholangitis Treatment in Hainan Bo'ao Lecheng Pilot Zone
-
October 31, 2025
Gilead Sciences Announces Third Quarter 2025 Financial Results
-
October 10, 2025
Gilead's Long-Acting HIV Prevention Medicine is Named One of TIME's Best Inventions of 2025
-
August 28, 2025
Seladelpar Granted Approval for Primary Biliary Cholangitis Treatment in Beijing Tianzhu Rare Disease Drug Guarantee Pilot Zone
-
August 07, 2025
Gilead Sciences Announces Second Quarter 2025 Financial Results
-
July 24, 2025
Twice-Yearly Lenacapavir for HIV Prevention is Now Launched in Hainan Bo’ao Lecheng Pilot Zone
-
July 01, 2025
TIME Names Gilead Sciences as a 2025 Most Influential Company
-
June 29, 2025
Twice-Yearly Lenacapavir for HIV Prevention Is Now Approved at Hainan Bo’ao Lecheng Pilot Zone
